The 2019 Academician Spring City Tour and Academician Forum were held, and Yinfeng Biotech Group teamed up with Academician Li Changming on site to assist in the development of the big health industry
Release time:
2019-11-28
Gathering global talents and promoting the development of Quancheng. The 2019 Academician Spring City Tour and Academician Forum was held in Jinan on November 28. The event was organized by the Shandong Academician Expert Federation and the Jinan Talent Work Leading Group Office, hosted by Academician Home (Jinan) and the Jinan Science and Technology Bureau. Yinfeng Biotech Group, as a representative of Jinan's biomedical enterprise, was invited to participate.
Adhering to the principles of "high-end, precise, professional, and specialized", focusing on key areas such as big data and new generation information technology, intelligent manufacturing and high-end equipment, biomedicine, etc., the event organizer invited 11 academicians and corresponding domestic and foreign experts to come to Jinan for precise docking and negotiation with enterprises and institutions in Jinan.
At the event, Wang Baoqing, President of Yinfeng Biotechnology Group, and Academician Li Changming signed a contract on-site to jointly build the "Qingda Yinfeng" Biotechnology Industry Research Institute.
In the future, both sides of the cooperation will uphold the advantages of all parties, rely on the "Qingda Yinfeng" Biotechnology Industry Research Institute, take market demand as the guide, and industrialization as the goal, establish research topics and jointly tackle key problems. Establish a mechanism for high-end talent and technology exchange and circulation, undertake national science and technology plans or key projects, jointly build international talent and technology certification and training bases, deepen the integration of industry, academia and research, and school enterprise cooperation, and jointly promote the development of biomedical and health undertakings.
Professor Li Changming, Dean of the Frontier Interdisciplinary Research Institute at Qingdao University, Academician of the American Academy of Medicine and Biotechnology, Fellow of the Royal Society of Chemistry in the UK, Fellow of the International Thin Film Society, and highly cited scientists from Thomson Reuters, CoryVision, and Elsevier in Global Materials and Interdisciplinary Studies. There are over 670 highly influential SCI articles, over 200 patents, more than 30500 citations, an H-factor of 85, and 8 published monographs. He used to be the chief scientist of Motorola in the United States, the tenured professor and the director of the Department of Bioengineering of Nanyang Technological University in Singapore, the director of the Advanced Biological Nanosystem Research Center, the honorary researcher of the Chinese Academy of Sciences, the evaluation expert of the national key scientific research projects, the evaluation expert of the national level distinguished professors, the evaluation expert of the national Yangtze River distinguished and chair professors, and the evaluation expert of the national award. Received Motorola's highest invention award, Singapore Nanyang Research and Innovation Award, China Overseas Chinese Innovation Talent Contribution Award, and China Industry University Research Cooperation Innovation Award (2017). Hosted or participated in more than 80 major projects funded by the National Natural Science Foundation of China, the "973" Program, as well as research projects in Singapore, the United States, and Australia, totaling over 300 million scientific research funds. Editorial board member of the internationally renowned English scientific journal "RSC Advances", advisory member of "Nanoscale" and "Nanoscale Advances" (RSC), and advisory member of "Joule" (Cell), English material report: Energy editor in chief. As a globally renowned scientist, we have extensive scientific research cooperation with the United States, Britain, Russia, Europe, Canada, Australia, Singapore, and other countries internationally.
On the day of signing, Qingdao University awarded Shandong Yinfeng Life Science Research Institute, a subsidiary of Yinfeng Biological Group, as the "Qingdao University Collaborative Innovation Base" and "Qingdao University Practice Teaching Base".
Latest developments
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
